Chicklittle,I am concerned by your post, because that is not...

Chicklittle,

I am concerned by your post, because that is not what the report said at all, it didnt even indicate it was evaluated as against another patch or patches at all, it said "OTC Drug".

Starts-
The study tested the delivery performance of OBJs
Dermaportation and ETP technologies in a fully formulated patch format, when compared to an existing Over the Counter (OTC) drug product with significant international sales.

In 2008, OBJ advised the market that it had entered into an Agreement with a major international FMCG company to evaluate OBJs two main technologies and had engaged
Azopharma Contract Services Inc as the independent Contract Research Organisation (CRO) to
undertake the formulation and evaluation phases.

The FMCG companys stated objective in the Agreement with OBJ was to achieve up to a 10- fold increase in drug delivery over an existing commercial product.

Ends

Further it said

The Azopharma Report, which remains the property of the FMCG company, stated in the Executive Summary that:

The developed patch system effectively fluxes
approximately a 10-fold over the existing product
comparatively

Ends

So it may weel have been a oral tablet that is taken every 6 hours, and it said that it was an "approximate" increase

link to obj report

http://www.obj.com.au/US%20Study%20Results.pdf

Read the link and you will find that your comment is wrong

"OBJ IS 10X more effective than ANY OTHER TDD patch" this is not what the report said at all

it said this

"OBJ is restricted from disclosing any information relating to the drug tested, the comparative product or the market."

so it could have been a gel, a pill etc